Skip to main content
    C

    Cellectis SA (CLLS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.06
    +0.02 (+1.92%)

    Market Cap: $118.86M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Cellectis SA (CLLS) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Cellectis SA (CLLS) has a market cap of $118.86M and an enterprise value of $35.35M. It kept -474.44% of revenue as net income over the last 12 months. Revenue fell 64.32% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 70.26% below the market cap, as cash exceeds debt.

    Market Cap$118.86M
    Enterprise Value$35.35M
    Latest price (Nov 17, 2026)$1.06

    Key Dates

    Last Earnings DateNov 12, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.06% in the quarter ended Sep 30, 2026 and grew 0.31% a year over 2 years.

    Shares Outstanding100.71M
    Shares Change (YoY)+0.39%
    Shares Change (QoQ)+0.06%
    Share Count Growth (2Y CAGR)+0.31%

    Valuation Ratios

    The price to sales ratio is 4.0x. Its year-end P/S ranged from 4.3x to 251.1x from 2016 to 2025.

    P/S Ratio4.0x
    Forward P/S2.3x

    Price Statistics

    The stock is down 72.82% over 52 weeks and trades 22.06% below its 50-day average.

    Beta (1Y)2.36
    52-Week Change-72.82%
    1-Month Change+14.53%
    3-Month Change-66.56%
    6-Month Change-70.80%
    5-Year Change-89.96%
    10-Year Change-93.89%
    Total Return (1Y)-72.82%
    Total Return (3Y CAGR)-28.74%
    Total Return (5Y CAGR)-34.97%
    Return vs SPY (1Y)-85.77%
    Max Drawdown (1Y)-82.70%
    Max Drawdown (3Y)-82.70%
    Sharpe Ratio (1Y)-1.42
    Correlation with SPY (1Y)0.34
    50-Day Average$1.36
    200-Day Average$2.89
    52-Week Range$0.88 to $5.45
    RSI (14 Days)43.1
    Average Volume (20 Days)81.21K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.15x current liabilities.

    Current Ratio1.15x
    Quick Ratio1.15x
    Interest Coverage-16.16x

    Returns and Efficiency

    Return on invested capital is -287.29% over the last 12 months, against a 5-year average of -44.77%.

    Return on Assets (ROA)-59.70%
    Return on Invested Capital (ROIC)-287.29%
    ROE (5Y Average)-71.82%
    ROA (5Y Average)-24.20%
    ROIC (5Y Average)-44.77%
    Asset Turnover0.10x
    Receivables Turnover3.02x

    Scores

    CLLS has an Altman Z-Score of -3.95, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score-3.95
    Altman Z ZoneDistress
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $26.85M over the last 12 months.

    Revenue$26.85M
    Revenue Growth (YoY)-64.32%
    Gross Profit$14.90M
    Operating Income-$127.41M
    Pretax Income-$131.18M
    Net Income-$127.41M
    EBITDA-$117.57M
    Reported EPS (TTM)-$0.63

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$146.71M
    Total Debt$63.20M
    Net Cash$83.51M
    Working Capital$21.89M
    Shareholder Equity-$17.63M
    Tangible Book Value-$18.44M
    Total Assets$213.43M
    Total Liabilities$231.06M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $2.40M of capital spending, operating cash flow left -$58.89M of free cash flow.

    Operating Cash Flow-$56.49M
    Capital Expenditures$2.40M
    Free Cash Flow-$58.89M
    FCF Per Share-$0.81
    Depreciation and Amortization$45.70M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -474.46%.

    Gross Margin55.48%
    Operating Margin-474.46%
    Pretax Margin-488.49%
    Net Margin-474.44%
    EBITDA Margin-437.80%
    FCF Margin-219.30%

    Growth

    Revenue grew 56.12% a year over 3 years.

    Revenue Growth (3Y CAGR)+56.12%
    Revenue Growth (5Y CAGR)-0.27%

    Revenue and profit by year

    Dividends and Yields

    CLLS does not pay a dividend. Its free cash flow yield is -55.17%.

    FCF Yield-55.17%
    Shareholder Yield0.00%

    Peer Position

    Against 4 similar companies, CLLS has the 4th highest P/S.

    P/S Ratio4.0x vs 28.7x median
    ROIC-287.29% vs -46.74% median
    Revenue Growth (Trailing 4 Quarters, YoY)-64.32% vs -99.55% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 22.93% a year over the next 5 fiscal years.

    Revenue Growth Forecast (5Y CAGR)+22.93%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About CLLS

    What is CLLS's market cap?

    Cellectis SA has a market cap of $118.86M. Its enterprise value, which adds debt and subtracts cash, is $35.35M.

    How many shares of CLLS are outstanding?

    Cellectis SA has 100.71M shares outstanding. The count is up 0.39% from a year earlier.

    Does CLLS pay a dividend?

    No. Cellectis SA does not pay a dividend.

    How much debt does CLLS have?

    Cellectis SA has $63.20M of total debt and $146.71M of cash and equivalents, a net cash position of $83.51M.